Literature DB >> 16518703

Associations of the -174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly.

Giovanni Ravaglia1, Paola Forti, Fabiola Maioli, Martina Chiappelli, Paolo Dolzani, Mabel Martelli, Marisa Bianchin, Erminia Mariani, Luigi Bolondi, Federico Licastro.   

Abstract

Serum interleukin-6 (sIL6) is an acknowledged predictor of all-cause mortality in older age. A common G/C polymorphism has been identified at position -174 of the IL6 gene promoter (IL6-174G>C), but its associations with sIL6 and mortality are still unclear. Data from a population-based elderly cohort (n=824) were used to study the associations of baseline sIL6 with the IL6-174 C-allele (C+) carrier status and all-cause mortality at 4 years, in the presence and absence of preexisting major diseases (PMD). Analyses were adjusted for socio-demographic factors and body-mass-index. Three-hundred-eighty-eight participants (47.1%) had PMD. Compared to the bottom sIL6 quartile, mortality increased both in presence [Hazard Ratio (HR)=3.04; 95% confidence interval (CI): 1.48-6.25] and absence of PMD [HR=3.91; 95%CI: 1.42-10.72] for the third higher sIL6 quartile, but only in presence of PMD for the top sIL6 quartile [HR=2.30; 95%CI: 1.09-4.83]. In absence of PMD, C+ carrier status did not affect both sIL6 and mortality. In presence of PMD, C+ carrier status was associated with increased baseline sIL6 [odds ratio 2.01; 95%CI: 1.25-3.22, for all sIL6 quartiles above the bottom] but not with increased mortality risk. A survival advantage was even found for C+ carriers with PMD and sIL6 in the top quartile [HR=0.31, 95%CI: 0.13-0.76]. In conclusion, although associated with increased sIL6 levels in presence of major diseases, the IL6-174 C-allele does not seem to have direct detrimental effects on survival in older age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16518703     DOI: 10.1007/s10522-005-4908-x

Source DB:  PubMed          Journal:  Biogerontology        ISSN: 1389-5729            Impact factor:   4.277


  9 in total

1.  Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings.

Authors:  Heather S L Jim; Jong Y Park; Jennifer Permuth-Wey; Maria A Rincon; Kristin M Phillips; Brent J Small; Paul B Jacobsen
Journal:  Brain Behav Immun       Date:  2012-03-28       Impact factor: 7.217

2.  Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers.

Authors:  Christine Miaskowski; Marylin Dodd; Kathryn Lee; Claudia West; Steven M Paul; Bruce A Cooper; William Wara; Patrick S Swift; Laura B Dunn; Bradley E Aouizerat
Journal:  J Pain Symptom Manage       Date:  2010-06-08       Impact factor: 3.612

3.  Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies.

Authors:  Guo-hua Zheng; Hai-ying Chen; Shang-Quan Xiong
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

4.  Polymorphisms of tumor necrosis factor-alpha and interleukin-6 gene and C-reactive protein profiles in patients with idiopathic dilated cardiomyopathy.

Authors:  Afrose Liaquat; Gul Zareen Asifa; Asyia Zeenat; Qamar Javed
Journal:  Ann Saudi Med       Date:  2014 Sep-Oct       Impact factor: 1.526

5.  The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis.

Authors:  Zulvikar Syambani Ulhaq; Gita Vita Soraya; Lely Retno Wulandari
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

6.  An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6.

Authors:  Benjamin P Fairfax; Fredrik O Vannberg; Jayachandran Radhakrishnan; Hakon Hakonarson; Brendan J Keating; Adrian V S Hill; Julian C Knight
Journal:  Hum Mol Genet       Date:  2009-11-26       Impact factor: 6.150

7.  IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease.

Authors:  Beatriz Piantoni Gonçalves; Tamires Flauzino; Cláudia Junko Inoue; Jaqueline Costa Castardo de Paula; Talita Cristina Galvão; Camila Cataldi de Alcantara; Paula Kikuchi Miyazaki; Lucilene Rosa; Silva Westmore; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Andréa Name Colado Simão
Journal:  Int J Colorectal Dis       Date:  2020-10-12       Impact factor: 2.571

8.  Genome-wide association with select biomarker traits in the Framingham Heart Study.

Authors:  Emelia J Benjamin; Josée Dupuis; Martin G Larson; Kathryn L Lunetta; Sarah L Booth; Diddahally R Govindaraju; Sekar Kathiresan; John F Keaney; Michelle J Keyes; Jing-Ping Lin; James B Meigs; Sander J Robins; Jian Rong; Renate Schnabel; Joseph A Vita; Thomas J Wang; Peter W F Wilson; Philip A Wolf; Ramachandran S Vasan
Journal:  BMC Med Genet       Date:  2007-09-19       Impact factor: 2.103

9.  Inflammatory genetic markers of prostate cancer risk.

Authors:  Elizabeth A Tindall; Vanessa M Hayes; Desiree C Petersen
Journal:  Cancers (Basel)       Date:  2010-06-08       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.